Brief: Isofol Announces Licensing Agreement For Paladin Labs

Isofol Medical AB (publ)

02/11/2020 12:07

Nov 2 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * ISOFOL ANNOUNCES LICENSING AGREEMENT FOR PALADIN LABS INC.
TO
COMMERCIALIZE ARFOLITIXORIN IN CANADA
    * MAY RECEIVE UP TO $US 23.05 MILLION** (SEK 205 MILLION**)
AS
UPFRONT, DEVELOPMENT, REGULATORY AND SALES-BASED MILESTONE
PAYMENTS
    * DEFINITIVE LICENSE AGREEMENT WITH ENDO VENTURES LIMITED, A
SUBSIDIARY OF ENDO INTERNATIONAL PLC (NASDAQ: ENDP) PLC
    * IN ADDITION, ISOFOL WILL RECEIVE TIERED ROYALTIES ON NET
SALES
IN SOLID DOUBLE-DIGIT FIGURES

Source text for Eikon:  ID:nWkr2jNr6f 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))